Artwork

Innhold levert av The Immunology Podcast. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av The Immunology Podcast eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Player FM - Podcast-app
Gå frakoblet med Player FM -appen!

Ep. 64: “Brain Tumor Immunotherapy” Featuring Dr. Peter Fecci

1:07:43
 
Del
 

Manage episode 379409222 series 2895470
Innhold levert av The Immunology Podcast. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av The Immunology Podcast eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

Guest:

Dr. Peter Fecci is a Professor of Neurosurgery at Duke University and the Director of the Duke Center for Brain and Spine Metastasis. His research focuses on brain tumor immunology and immunotherapy, and T cell dysfunction in glioblastoma and other intracranial cancers. He talks about activating T cells to target brain tumors and his team’s work on targeting MHC-I-negative tumor cells.

Featured Products and Resources:

The Immunology Science Round Up

A Universal Flu Vaccine Candidate – A group 2 hemagglutinin universal influenza virus vaccine candidate protects mice against group 2 influenza viruses.

Regulatory T Cells in Muscle Function – Exercise induces a highly functional and stable muscle Treg phenotype.

An Antiviral Drug and SARS-CoV-2 Mutations – Scientists identified a mutational spectrum from viruses in patients treated with molnupiravir.

Microbial Exposure and Allergic Inflammation – Increased microbial biodiversity in mice does not protect against allergic inflammation, in contrast to what would be predicted by the hygiene hypothesis.

Image courtesy of Dr. Peter Fecci

Subscribe to our newsletter!

Never miss updates about new episodes.

Subscribe
  continue reading

109 episoder

Artwork
iconDel
 
Manage episode 379409222 series 2895470
Innhold levert av The Immunology Podcast. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av The Immunology Podcast eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

Guest:

Dr. Peter Fecci is a Professor of Neurosurgery at Duke University and the Director of the Duke Center for Brain and Spine Metastasis. His research focuses on brain tumor immunology and immunotherapy, and T cell dysfunction in glioblastoma and other intracranial cancers. He talks about activating T cells to target brain tumors and his team’s work on targeting MHC-I-negative tumor cells.

Featured Products and Resources:

The Immunology Science Round Up

A Universal Flu Vaccine Candidate – A group 2 hemagglutinin universal influenza virus vaccine candidate protects mice against group 2 influenza viruses.

Regulatory T Cells in Muscle Function – Exercise induces a highly functional and stable muscle Treg phenotype.

An Antiviral Drug and SARS-CoV-2 Mutations – Scientists identified a mutational spectrum from viruses in patients treated with molnupiravir.

Microbial Exposure and Allergic Inflammation – Increased microbial biodiversity in mice does not protect against allergic inflammation, in contrast to what would be predicted by the hygiene hypothesis.

Image courtesy of Dr. Peter Fecci

Subscribe to our newsletter!

Never miss updates about new episodes.

Subscribe
  continue reading

109 episoder

Alle episoder

×
 
Loading …

Velkommen til Player FM!

Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.

 

Hurtigreferanseguide

Copyright 2024 | Sitemap | Personvern | Vilkår for bruk | | opphavsrett